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Protein kinase C (PKC) isozymes are the paradig-
matic effectors of lipid signaling. PKCs translocate
to cell membranes and are allosterically activated
upon binding of the lipid diacylglycerol to their C1A
and C1B domains. The crystal structure of full-length
protein kinase C bII was determined at 4.0 A˚,
revealing the conformation of an unexpected inter-
mediate in the activation pathway. Here, the kinase
active site is accessible to substrate, yet the confor-
mation of the active site corresponds to a low-
activity state because the ATP-binding side chain
of Phe629 of the conserved NFD motif is displaced.
The C1B domain clamps the NFD helix in a low-
activity conformation, which is reversed upon
membrane binding. A low-resolution solution struc-
ture of the closed conformation of PKCbII was
derived from small-angle X-ray scattering. Together,
these results show how PKCbII is allosterically regu-
lated in two steps, with the second step defining
a novel protein kinase regulatory mechanism.
INTRODUCTION
The formation of small-molecule second messengers is one of
the most important consequences of the activation of cell-
surface receptors. Many of the most prominent second messen-
gers are lipids, and the paradigmatic lipid second messenger is
sn-1,2 diacylglycerol (DAG). DAG activates a variety of cellular
effectors, including kinases and GTPase-activating proteins
(GAPs) and guanine nucleotide exchange factors (GEFs) for
small G proteins (Yang and Kazanietz, 2003). By far the most
widely distributed class of DAG effectors are the protein kinase
C (PKC) isozymes (Rosse et al., 2010). Intensively studied for
the past three decades, PKCs are the archetypal allosteric trans-
ducer of lipid second messenger signaling (Newton, 1995; Nish-
izuka, 1992). In keeping with their widespread tissue distribution,
PKCs regulate a remarkable range of physiological pathways,
including, but not limited to, T cell recognition, cell polarity, cell
migration, proliferation and differentiation, neuronal signaling,
and metabolism (Rosse et al., 2010).PKCs are serine/threonine kinases of the AGC family (Pearce
et al., 2010). The AGC family includes protein kinases A, B, C,
D, and G and is characterized by a C-terminal extension of the
kinase domain that contains one or two regulatory phosphoryla-
tion sites, important for kinase activity (Pearce et al., 2010). Like
other kinases, PKCs require phosphorylation of a conserved
Ser/Thr in the activation loop for activity (Pearce et al., 2010).
PKCs are grouped into subclasses based on the domain compo-
sition of the regulatory portion and their respective cofactor
requirements (Hurley and Grobler, 1997; Mellor and Parker,
1998; Newton, 1995). The conventional PKCs (a, bI, bII, g) are
regulated via two DAG-binding C1 domains (Hurley et al.,
1997) and aCa2+- and phospholipid-bindingC2 domain (Nalefski
and Falke, 1996) (Figure 1A). The novel, Ca2+-independent PKCs
(d, 3, h, q) have an N-terminal C2 domain that does not bind Ca2+
or phospholipids, and two typical DAG-binding C1 domains. The
Ca2+/DAG-independent atypical isoforms (z, l/i) have a single
atypical C1 domain that does not bind DAG and lack a C2
domain. All PKCs have a pseudosubstrate region, in which the
phosphorylatable Ser/Thr is replaced by an Ala, which maintains
the inactive state in the absence of an activating signal (Newton,
1995; Orr and Newton, 1994). PKCs are primed for activation by
the phosphorylation of three residues (Tsutakawa et al., 1995).
First, the activation loop Ser/Thr is phosphorylated by PDK1
(Chou et al., 1998; Le Good et al., 1998), and then the C-terminal
turn and hydrophobic motif are phosphorylated by mTORC2
(Facchinetti et al., 2008; Ikenoue et al., 2008). Primed PKCs
are activated to phosphorylate their substrates when their regu-
latory domains engage the appropriate combination of signals.
Signal engagement triggers the release of the pseudosubstrate
sequence from the active site, allowing access to substrates.
In the case of the conventional PKCs, these signals are DAG,
Ca2+, and phospholipids (Hurley and Grobler, 1997; Mellor and
Parker, 1998; Newton, 1995).
The question of how signal engagement triggers kinase activa-
tion at the structural level has preoccupied many laboratories,
and a large body of fragmentary structural information is avail-
able for the isolated domains of PKCs. Structures have been
solved of the catalytic domains of PKCs bII, q, and i (Grodsky
et al., 2006; Messerschmidt et al., 2005; Takimura et al., 2010;
Xu et al., 2004), the C2 domains of PKCs a, bII, d, h, and 3 (Guer-
rero-Valero et al., 2009; Littler et al., 2006; Ochoa et al., 2001;
Pappa et al., 1998; Sutton and Sprang, 1998; Verdaguer et al.,
1999), and the C1 domains from PKCs a (Hommel et al., 1994),Cell 144, 55–66, January 7, 2011 ª2011 Elsevier Inc. 55
Figure 1. Structure of PKCbII
(A) Schematic of the domain structure of PKCbII.
(B) Structure of the ordered portion of full-length PKCbII, comprising the C1B (blue), C2 (green), and kinase domains. Magenta denotes theC lobe and yellow the N
lobe of the kinase domain. The NFD helix is colored cyan, calcium ions salmon, and AMPPNP orange. Phospho-Thr500, -Thr641, and -Ser660 are shown in a stick
model.
(C) Difference map (Fo-Fc) phased using a model subjected to a single pass of DEN-restrained refinement, prior to inclusion of residues 620–639. The map is
contoured at 2s.
See also Figure S1 and Figure S2.g (Xu et al., 1997), and d (Zhang et al., 1995) alone or bound to the
DAG-mimetic phorbol ester. This information has been difficult
to integrate into a high-resolution picture of the activation
pathway because of various technical challenges in the crystal-
lization of full-length PKCs. In addition to the usual challenges of
crystallization of multidomain proteins, suitable PKC samples for
crystallization must be stoichiometrically phosphorylated at the
activation loop, turn, and hydrophobic sites. Proteolysis in the
highly labile V3 region connecting the regulatory and catalytic
domainsmust be avoided. The Zn2+ ions required for the stability
of the C1 domains must be retained. We optimized sample puri-
fication according to these criteria and were able to crystallize
full-length rat PKCbII, an isozyme that has been the subject of
especially intensive mechanistic analysis. Moreover, PKCbII is
the target for the investigational diabetes drug ruboxistaurin
(Das Evcimen and King, 2007).
Crystals of PKCbII diffracted only to 4.0 A˚, but by taking
advantage of improved methodology for low-resolution crystal-
lographic refinement, the data proved adequate to map a previ-
ously unobserved conformation of a helix encompassing the
conserved NFD motif of the AGC kinase family. Unexpectedly,
lattice contacts between the C2 and catalytic domains led to
the observation of what appeared to be a partially activated56 Cell 144, 55–66, January 7, 2011 ª2011 Elsevier Inc.conformation. We were able to confirm the structural inference
that the observed conformation is part of the physiological acti-
vation pathway by mutational analysis of PKCbII translocation.
Thus, this structure provides a snapshot of an intermediate in
the lipid activation pathway of PKCbII. The analysis identified
an unexpected mechanism of allosteric regulation through plas-
ticity of the NFD motif region. In order to fill out the structural
picture of the PKCbII activation pathway, small-angle X-ray scat-
tering (SAXS) was used, in conjunction with constraints provided
by the crystal structure, to determine a low-resolution structure
of the closed, autoinhibited conformation. Together, these struc-
tural analyses allow us to map out a conformational activation
pathway that is more complex than anticipated.
RESULTS
Structure of PKCbII
PKCbII samples were confirmed for integrity with respect to
intact primary structure, stoichiometric Zn binding, phorbol
ester-dependent membrane binding and kinase activity, phos-
phorylation at the three canonical sites on the catalytic domain,
and monodispersity (Figure S1 available online). Crystals of
a maximum dimension of 20 mm were grown, and diffraction
Table 1. Crystallographic Data Collection and Refinement
Statistics
Data Collection
Space group P3221
Unit cell (a, b, c in A˚) 114.27, 114.27, 170.84
Resolution range (A˚) 57.1–4.0
Observations 46215
Unique reflections 10117
Completeness (%)a 95.0 (88.0)
I/sI 3.5 (1.8)
Rsym (%) 19.2 (39.3)
Structure Refinement
Resolution range (A˚) 57.1–4.0
Reflections used 10670
R factor, Rfree
b (%) 19.4 (25.0)
Model residues 101–292, 339–669
Rms Deviations
Bond lengths (A˚) 0.012
Bond angles (deg) 0.878
a Values in parentheses refer to the highest resolution shell.
b Rfree = free R factor based on random 5% of all data.data were collected to 4.0 A˚ (Table 1) on the GM/CA-CAT
dedicated microbeam (ID23-B) at the Advanced Photon Source
(APS) and the structure was solved by molecular replacement
using the coordinates of the PKCbII kinase domain (Grodsky
et al., 2006) (Protein Data Bank (PDB): 2I0E) and the PKCbII C2
domain (Sutton and Sprang, 1998) (PDB: 1A25). Electron density
was visible for the kinase domain, the C2 domain, and a single
C1 domain (Figures 1B and 1C; Figure S2A). The identity and
orientation of the C1 domain was confirmed using an anomalous
difference Fourier synthesis to locate the two native Zn atoms
(Figure S2B). Following refinement, density for the C1-C2 linker
became evident. The short, direct connection between the C1
and C2 domains identified the single ordered C1 domain as
the C1B domain and confirmed that these domains belonged
to the same PKCbII molecule. The use of deformable elastic
network (DEN) (Schroder et al., 2010) restraints for the C2 and
catalytic domains, representing the majority of the scattering
matter, led to electron density maps of a substantially higher
quality than expected at 4.0 A˚ (Figure 1C).
The initial map calculated following DEN refinement with
a model lacking residues 620–639 revealed a novel and well-
ordered conformation for this entire region (Figure 1C). The
sequence could be assigned to this region, in spite of the limited
resolution. Clear side-chain density was visible for Phe629,
Phe632, and Phe633, providing an unambiguous set of markers
to assign the primary sequence to the model. Residues 624–
634 are helical, and the register of these residues was therefore
defined with high confidence. Because these residues include
the conserved motif NFD (residues 628–630; see Figure 2E), we
refer to them as the ‘‘NFD helix.’’ Side-chain features were less
obvious for the sections 620–623 and 635–639. However, the
main-chain density was nearly continuous and the start and
end points of these sections were anchored either to landmarksin the catalytic domain or to the assigned sequence in the new
helix. Therefore these assignments also have a high confidence
level. The C1B-C2 connector 151–158 has poorer density and
its register is not assigned with high confidence. As described
below, the configuration of the C1B-C2 linker in this structure is
probably not physiologically relevant, so this limitation of the
model does not affect its functional interpretation. The DEN
refinement led to an excellent free R factor of 0.25. Nevertheless,
the pseudosubstrate and C1A domains and the V3 (C2-kinase)
linker were completely absent from the electron density.
The kinase domain adopts the intermediate open conforma-
tion, as also observed in the bisindolymaleimide-bound isolated
kinase domain structure (Figures 2A and 2B) (Grodsky et al.,
2006),withminor exceptions notedbelow. The lattice is stabilized
by contacts between theC2domain of onePKCand twodifferent
instances of the catalytic domain (Figure S2A). The Ca2+-binding
regions (CBRs) of the C2 span the two lobes of the first instance
of the catalytic domain (Figure S2A, contact 1). The burial of
the C2-bound Ca2+ ions in an interface with the catalytic
domain would be inconsistent with the physiological function
of these ions in bridging PKC to the membrane (Nalefski and
Falke, 1996), therefore we dismissed this lattice contact as
functionally irrelevant. The other major lattice contact involves
nonconserved polar residues of both the C2 domain and the
catalytic domain (Figure S2A, contact 2). Because theC2 domain
is a conserved and functionally important feature of conventional
and novel PKCs, we anticipated that functionally relevant
contacts should include at least some conserved residues. This
second contact is formed by someof the least conserved regions
on both the C2 and catalytic domains, and therefore we judged
its functional relevance to be implausible. Moreover, the confor-
mation of the C2 domain in this structure is not judged to repre-
sent the closed, fully autoinhibited conformation of PKCbII. As
described below, this conformation is not consistent with SAXS
analysis of PKCbII in solution. Rather, it probably represents
a snapshot of the behavior of theC2 domain in the activated state
as trapped by lattice contacts. Strong difference density in
a phosphate omit map is observed for the activation loop, con-
firming the phosphorylation of Thr500 (Figure S2C). Difference
omit density is also observed for the C-terminal tail of the kinase,
confirming the presence of the canonical turn and hydrophobic
motif phospho-Thr641 and phospho-Ser660 (Figures S2D and
S2E). The active site contains bound AMPPNP and Mg2+;
however, the Mg2+ ions could not be positioned accurately into
the model given the limitation of 4.0 A˚ resolution.
The NFD Helix
One of the unexpected features of this structure is the unusual
positioning of the residues of the NFD motif (Figure 2),
a conserved catalytic element of the AGC kinases. In the present
structure, the NFD helix preceding residues in the C-terminal tail
of PKCbII is in what we refer to as the ‘‘clamped’’ conformation
(Figures 2A and 2B). The clamp keeps the NFD Phe629 out of
the active site, but it is in intimate and extensive contact with
both the C1B and catalytic domains. The Phe residue of this
motif is normally part of the active site and binds the adenine
of ATP, on the basis of the ATP-PKCi complex (Takimura
et al., 2010), and it is not part of a helix. We refer to the activeCell 144, 55–66, January 7, 2011 ª2011 Elsevier Inc. 57
Figure 2. The Kinase Catalytic Domain and the NFD Helix
(A) Comparison of the NFD helix in the isolated PKCbII catalytic domain structure (gray) and the present full-length PKCbII structure, where the NFD helix and
adjacent regions are colored cyan.
(B) Close-up of the NFD region.
(C) Comparison of the NFD region in full-length PKCbII (cyan) and the ATP-bound kinase domain of PKCi (orange) (Takimura et al., 2010).
(D) Phe629 of PKCbII corresponds to Phe327 of PKA and Phe543 of PKCi.
(E)Sequencealignmentof theNFDregionofmammalianPKCsandPKCs fromC.elegansandC.albicans (yeast), compared toAGCkinase familymembersPKAand
Akt. An invariant proline corresponding to PKCbII Pro619 is at the start of the AGC-specific tail. The inactive NFD helix of our structure is indicated on the alignment
(cyan box corresponds to helix in C), as are the rearranged, active NFD motifs of PKCi (orange boxes correspond to helices in C and D) and Akt2 (orange boxes).
58 Cell 144, 55–66, January 7, 2011 ª2011 Elsevier Inc.
Figure 3. The C1B Clamp
(A and B) The interface between the C1B domain and the N lobe of the catalytic domain stabilizes the clamp by positioning the C1B appropriately with respect to
the NFD helix. This interface is predominantly hydrophobic, with the N lobe side chains of Leu345, Leu358, Leu367, and Y422 (yellow, stick model) packing
against Leu125, Ile126, and K141 (blue, surface model) of the C1B domain. Y430 is contributed by the C lobe of the kinase domain (magenta).
(C) The C1B domain clamps the NFD helix and residues immediately N-terminal to the helix. Residues Pro619–Cys622 (cyan, stick model) are in an extended
conformation that makes intimate contacts with the phorbol ester-binding cleft of the C1B domain.
(D) Comparison of the C1B domain of PKCd bound to PMA (Zhang et al., 1995) with that of PKCbII shows a steric clash between phorbol ester and residues
619–622 running through the cleft.conformation of the NFD motif as the ‘‘in’’ conformation (Fig-
ure 2C). Grodsky et al. (2006) first reported that this sequence
could form a helix, in the context of the isolated PKCbII catalytic
domain. In the isolated catalytic domain structure (Grodsky et al.,
2006), the Phe is remote from the active site and forms part of
a novel helix. We will refer to this as the ‘‘out’’ conformation (Fig-
ure 2A). The out conformation has no known regulatory rele-
vance but does illustrate that this region has an intrinsic propen-
sity to form a helix under appropriate conditions.
C1B Contacts with the Catalytic Domain Mimic
Membrane and Phorbol Ester
The C1B and catalytic domain have an extensive interface made
up mainly of conserved hydrophobic residues. On the catalytic
domain side, the contact involves a conserved and mostly
nonpolar region on the outer face of the N lobe (Figures 3A and
3B). On the C1B side, residues from the conserved hydrophobic
tip of the domain, and adjoining residues, make contacts with the
catalytic domain and NFD helix. In particular, C1B membrane-
penetrating side chains of residues Leu125 and Ile126 makeextensive contacts with Phe629 of the NFD adenine-binding
motif. Finally, residues 619–622, immediately preceding the start
of the NFD helix, fill the DAG-binding site of the C1B domain (Fig-
ure 3C). The Pro619 carbonyl appears to accept a hydrogen
bond from the main-chain amide of Gly124, replacing the 3-
oxygen of phorbol ester as seen bound to the C1B domain of
PKCd (Zhang et al., 1995). The Ala621 main-chain NH appears
to donate a hydrogen bond to the main-chain carbonyl of
Gly124, serving as a counterpart of the 4-hydroxyl of phorbol
ester (Figure 3D). The C1B domain buries a total solvent-acces-
sible area of 1073 A˚2 in all contacts with the rest of PKCbII.
C1BClamps theNovel NFDHelix of theCatalytic Domain
in a Low-Activity Conformation
In the isolated PKCbII catalytic domain structure, residues 627–
636 form the NFD helix, which is in the ‘‘out’’ conformation and
has not been visualized in the structures of other kinase catalytic
domains. Residues 625–626 are disordered in the isolated
kinase domain. In the present full-length PKCbII structure, the
NFD helix comprises a slightly different set of residues, 624–634,Cell 144, 55–66, January 7, 2011 ª2011 Elsevier Inc. 59
Figure 4. Mutational Analysis of the C1B Clamp in PKCbII Translocation
(A) Plot of in vivo membrane translocation of PKCbII against PMA. Data points are the mean of two measurements, and error bars indicate the standard deviation
from the mean.
(B) PKCbII translocation was quantitated as the reduction in the cytosolic pool of PKC following exposure to PMA. Shown are the western blots for wild-type
PKCbII and the indicated mutants. The intensity of the normalized bands is plotted in (A). EC50 values are reported for each mutant. Both soluble cytosolic (S)
and membrane pellet (P) fractions are shown for L358D.and the helix shifts by up to 16 A˚ to occupy the clamped
conformation (Figures 2A and 2B). In the closed, catalytically
competent conformation of AGC protein kinases, the central
Phe of the NFD motif directly contacts the adenine of ATP
(Figures 2C and 2D). In the present structure, Phe629 is 12 A˚
away from the adenine moiety (Figure 2C). Phe629 corresponds
to Phe327 in PKA (Figure 2D). This Phe is conserved throughout
the AGC kinases. In PKA, Phe327 contacts the adenine of ATP.
For PKA, mutation of Phe327 weakens the interaction with ATP
and lowers catalytic efficiency 50-fold by increasing the Michae-
lis constant (Km) for ATP (Yang et al., 2009). The only structure
available of an isolated PKC catalytic domain bound to ATP is
that of PKCi, where the equivalent residue, Phe543 (Figures
2C–2E), directly contacts the adenine (Takimura et al., 2010). In
the PKCi-ATP complex, the NFD helix is unwound in the middle,
with the Phe and Asp of the NFD motif both in an extended
conformation. The residues immediately preceding them,
539–542, are in a 310-helical conformation oriented at a roughly
90 angle to the novel helix in full-length PKCbII (Figure 2C). Resi-
dues 534–542 are in a conformation that sterically overlaps with
thePKCbII C1Bconformation such that simultaneous occupancy
of the fully active ATP-bound and C1B-engaged conformation is
not possible. Downstream of the key ATP-binding Phe, one turn
of the NFD helix persists in the ATP-bound conformation, but
its path is different enough that the counterpart of the anchoring
Phe633 in PKCbII, Phe547 of PKCi, moves 8 A˚ and forms
a completely different set of contacts.Mutational Analysis of the C1B Clamp
The physiological significance of the C1B clamp was investi-
gated by analyzing the in vivo membrane translocation of wild-60 Cell 144, 55–66, January 7, 2011 ª2011 Elsevier Inc.type PKCbII and mutants designed to destabilize the interfaces
between the kinase N lobe, C1B domain, and AGC-specific
C-terminal tail containing the NFD helix. HEK293 cells express-
ing PKCbII and PDK1 were treated with phorbol 12-myristate
13-acetate (PMA). PMA-dependent membrane translocation
was quantitated by the decrease in the cytosolic pool of PKCbII
(Figures 4A and 4B). Deletion of two residues in the AGC linker
that passes through the cleft of the C1B domain (D621–622)
results in a 2-fold decrease in the concentration of PMA required
to mediate half-maximal translocation (EC50, Figure 4B). Muta-
tion of residues in the hydrophobic interface between the kinase
N lobe and the C1B domain (L358, L367D, Y422D, Y430D)
results in 5- to 14-fold decreases in the EC50 value. Within the
NFD helix, F629D and F633D led to 2- to 5-fold decreases in
EC50 (PMA). Mutation of Leu125 in the C1B domain, which is
part of the C1B clamp interface, was the only mutation that
increased EC50 (PMA). Indeed, the increase was dramatic,
more than 10-fold. This is consistent with its primary role in
membrane binding (Medkova and Cho, 1999; Xu et al., 1997).
The destabilization of PKCbII by mutations that disrupt the
C1B clamp confirms the physiological significance of this inter-
face in maintaining a secondary mode of autoinhibition in addi-
tion to the known mechanism of pseudosubstrate engagement
in the active site of the kinase domain.Solution Structure of PKCbII from Small-Angle X-Ray
Scattering
The solution structure of full-length PKCbII was analyzed using
SAXS (Figure 5). Ab initio determination of the molecular
envelope converged on a radius of gyration (RG) of 33 A˚
and a maximum particle dimension of 100 A˚ (Figure 5A).
The envelope did not, on its own, contain sufficient detail to posi-
tion the four structural domains (C1A, C1B, C2, and kinase).
Therefore, a new computational procedure, ensemble refine-
ment of SAXS (Ro´ _zycki et al., 2011), was applied in order to
determine the best fit of the structural domains and interdomain
linkers of PKCbII to the experimental SAXS curve, subject to
the constraints imposed by the position of the C1B domain in
the crystal structure. The pseudosubstrate was modeled in the
conformation seen for the interaction between the catalytic
and regulatory subunits of PKA (Kim et al., 2005, 2007). The posi-
tion of the C1Awas constrained by the shortness of the 8 residue
pseudosubstrate-C1A and 15 residueC1A-C1B linkers. TheC1B
and kinase domains were held fixed in their crystallographic
conformations. The C2 domain N terminus was constrained by
the 6 residue C1B-C2 connector. The C2 domain C terminus
was essentially unconstrained by the 46 residue V3 loop con-
necting it to the catalytic domain. The conformational space
occupied by these linked domains was exhaustively sampled
and the conformations that best fit the SAXS data were selected
(Figure 5D). The conformations that provided acceptable fits to
the SAXS I(q) curve (Figure 5B) also led to acceptable fits within
the ab initio molecular envelope (Figure 5C). All had in common
a conformation in which the C2 domain projected away from
the rest of PKCbII. In each case, the C2 domain made contact
with the C1B domain and/or associated linker regions but not
with the catalytic or C1A domains. More compact conformations
of the C2 domain relative to the rest of PKCbII did not lead to
acceptable fits, nor did attempts to fit a single compact confor-
mation combined with an ensemble of highly open structures. In
solution, the conformation of PKCbII is best described as a single
closed, autoinhibited state inwhich theC2 domain projects away
from, and has limited contact with, the rest of the structure.
DISCUSSION
The central finding in this study is that the NFD helix is a linchpin
of the regulation of PKCbII. The structural observation that the
C1B domain clamps the NFD helix in an inactive conformation
originated with the unexpected observation of a partially open
conformation for PKCbII. The relevance of this mechanism for
PKCbII in vivo was corroborated by mutational analysis of
contact residues on both the C1B domain and the NFD helix.
It was expected that destabilizing the C1B clampwould promote
its disengagement from the NFD helix and the rest of the catalytic
domain, lowering the energy barrier for translocation, and there-
fore lowering EC50 (PMA). Changing the register of the AGC
linker in the cleft of the C1B domain, mutation of the hydrophobic
side chains of Phe629 and Phe633 of the NFD helix, and muta-
tions in the core of the N lobe:C1B interface all serve to destabi-
lize PKCbII to such an extent that the EC50 values decrease by up
to 14-fold. These EC50 shifts provide strong corroboration for the
structural mechanism of regulation by NFD helix clamping.
The phorbol ester- andDAG-binding site on the C1B domain is
surrounded on three sides by an extremely hydrophobic rim
formed by the exposed side chains of (PKCbII numbering)
Pro112, Phe114, Tyr123, and Leu125. The counterparts of these
residues in related PKCs have been shown to contact lipid tails
by NMR in lipid micelles (Xu et al., 1997) and to penetrate thehydrocarbon core of membrane bilayers by surface pressure
studies (Medkova and Cho, 1999). The burial of Tyr123 and
Leu125 against the catalytic domain in the present partially
open structure renders them unavailable for membrane penetra-
tion. This situation is similar to the burial of the membrane-
binding surface of the C1 domain in the inactive conformation
of b2-chimaerin (Canagarajah et al., 2004). The C1 domain of
b2-chimaerin buries 1530 A˚2 of solvent-accessible surface
area in contacts with the rest of the molecule, almost 50%
more than for the PKCbII C1B. The more extensive C1 domain
burial in b2-chimaerin helps explain why its EC50 for PMA-
induced translocation is so much higher than for PKCbII,
1.2 mM as compared to 42 nM under otherwise similar condi-
tions. It also may explain in part why mutations that disrupt the
b2-chimaerin C1 domain interface yield larger EC50 decreases
of up to 80-fold, as compared to a maximum of 14-fold for
PKCbII. A full explanation of these differences will require the
structure of the completely closed conformation of PKCbII and
an assessment of the burial of the membrane-binding surface
of the C1A domain in that conformation. It is notable that, in
contrast to all other mutants tested, L125D shifts the PMA
dose-response curve to the right. This mutant is expected to
weaken membrane binding by the C1B domain at the same
time as it destabilizes the clamp. The right-shift produced by
L125D outweighs the potential left-shift caused by destabiliza-
tion of the C1B clamp. The role of the membrane-binding site
residues in clamping the inactive state highlights that dual and
opposing effects are to be expected upon mutating these resi-
dues. This duality probably underlies the sometimes contradic-
tory conclusions of various studies employing mutations to
dissect the relative roles of PKC C1A and C1B domains in
membrane translocation (Bogi et al., 1999; Szallasi et al., 1996)
and lipid activation (Medkova and Cho, 1999).
Upon activation, most of the NFD helix unwinds in order for
Phe629 to insert itself into the active site. This highlights the
NFD region as one of the most dynamic parts of the catalytic
domain and one of the most important for regulation of PKCbII.
The conservation of key residues involved in the clamp, such
as Phe633, suggests that NFD helix regulation extends in evolu-
tion as far as the aPKCs and Akts. The aPKCs and Akts lack
a C1B domain, and indeed the residues that insert into the
phorbol ester-binding site of the C1B are not as well conserved.
It is unclear what other domain or partner might take the place of
the C1B domain of the cPKCs and nPKCs in this context.
Conservation of the clamp residues is weaker still in PKA, where
the present conformation of the NFD helix is not observed, even
in the inactive holoenzyme (Kim et al., 2005). Observation of the
NFD helix has only been reported once before (Grodsky et al.,
2006), at which time its significance was not clear. These results
beg the question as to why NFD helix-mediated regulation has
not been reported in other kinases, and whether it is unique to
the PKCs and perhaps their closest relatives. The aC helix of
the PKCs appears to be unusually rigid, having been observed
in the catalytically active conformation in all PKC structures to
date (Grodsky et al., 2006; Messerschmidt et al., 2005; Takimura
et al., 2010; Xu et al., 2004). Perhaps NFD helix regulation of PKC
evolved as a substitute for what appears to be an inoperative aC
helix mechanism in this kinase subfamily. There have been threeCell 144, 55–66, January 7, 2011 ª2011 Elsevier Inc. 61
Figure 5. SAXS of PKCbII
(A) Pair distribution function (P(r)) for autoinhibited PKCbII. The radius of gyration is estimated to be 33.6 A˚ and 33.5 A˚ by Guinier analysis and the P(r) function,
respectively. The maximum dimension of the particle is estimated to be 100 A˚.
(B) Fit of the simulated scattering curves (I(q)) to the observed scattering of autoinhibited PKCbII. Experimental I(q) data points represent the mean of ten consec-
utive measurements of the same sample, and the error bars represent the standard error of the mean.
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Figure 6. Model for Multistep Activation of PKCbII
PKCbII translocates to the membrane upon Ca2+ release in the cell, where the calcium-binding regions of its C2 domain mediate bridging to the anionic phos-
pholipid phosphatidylserine, with an adjoining site on the C2 domain-binding phosphatidylinositol (4,5)-bisphosphate (1). Subsequent binding of DAG to the C1A
domain results in disengagement of the C1A domain (2), which in turn forces the removal of the pseudosubstrate (PS) from the catalytic cleft. Binding of a second
molecule of DAG by the C1B domain results in unclamping of the kinase:C1B assembly (3) and rearrangement of the NFD helix into the catalytically competent
state (4), triggering the phosphorylation of cellular targets (5) and subsequent downstream signaling. The C2 domain was docked to the membrane in the geom-
etry described by Landgraf et al. (2008) and the C1 domains as modeled by Zhang et al. (1995).major structural mechanisms described for regulation of kinase
activity: steric blockage of the active site, modulation of the
activation loop, and positioning of the aC helix (Huse and Kur-
iyan, 2002). To this list, we propose adding a fourth mechanism
for the PKCs and perhaps extending to the Akt/PKBs, regulation
by clamping of the NFD helix.
Solution structural analysis by SAXS is consistent with the
long-standing model for PKC activation, in which displacement
of the pseudosubstrate sequence is coupled to lipid binding by
the C1 domains and their displacement from contacts with the
catalytic domain (Hurley and Grobler, 1997; Newton, 1995; Orr
and Newton, 1994). In models for the activation of the Ca2+-
dependent cPKCs a, bI, bII, and g, the C2 domain rapidly
engages with the membrane following Ca2+ binding to the C2
domain CBRs (Nalefski and Newton, 2001; Oancea and Meyer,
1998). C2 binding initiates two-dimensional diffusion of the
cPKC on the membrane surface until the cPKC dissociates or
encounters a DAG molecule. The exposure of the Ca2+-binding
CBRs of the C2 domain in the SAXS structure of PKCbII is
consistent with such a function for the C2 domain. The current
structural results suggest that the next step in cPKC activation
is DAG engagement with the C1A domain, which both stabilizes(C) Superimposition of the best fit solution to the SAXS curve with an ab initio mole
one another. The assembly of PKCbII kinase and regulatory domains fits inside t
(D) A sample of the top solutions to the simulation of full-length, autoinhibited PK
blue).
See also Figure S1.membrane residency and pulls the pseudosubstrate out of the
active site (Figure 6). However, this is still insufficient for full acti-
vation, which requires yet another step. This last step is the
binding of the C1B domain to the membrane, unclamping of
the NFD helix, and engagement of Phe629 into the active site
(Figure 6). Taken together, the crystallographic and SAXS anal-
ysis leads to a picture of PKC activation that is fully consistent
with long-standing models for pseudosubstrate displacement
(Newton, 1995; Orr and Newton, 1994), while at the same time
revealing a novel and unexpected role for the NFD motif region
as an additional mode of allosteric regulation.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
Homo sapiens PDK-1 and Rattus norvegicus PKCbII containing a TEV-cleav-
able N-terminal glutathione S-transferase (GST) tag were cloned into the P10
and PH cassettes, respectively, of pFastBac Dual (Invitrogen). Wild-type and
a mutant PKCbII in which three surface-exposed Cys had been mutated to
Ser (C70S/C217S/C622S, the ‘‘SEC’’ mutant) were subcloned. Recombinant
bacmid was generated by transforming DH10 MultiBac cells (Berger et al.,
2004), and the Sf9 cells were transfected with the bacmid to generate baculo-
virus. Hi5 cells were infected with the baculovirus and grown in Express Fivecular envelope generated by DAMMIF, in two views rotated by 90 degrees from
he envelope.
CbII indicating the uncertainty in the placement of the C1A domain (shown in
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(Invitrogen) medium supplemented with 40 mM ZnCl2 for 72 hr at 28
C. For
purification, cells were lysed in 50 mM Tris, pH 7.4, 300 mM NaCl, 50 mM
NaF, 5 mM sodium pyrophosphate, 10 mM b-glycerophosphate, 1 mM
TCEP, 2 mM benzamidine, 2 mg/ml leupeptin, 0.5 mM sodium orthovanadate,
0.5% (w/v) CHAPS, and 1:100 protease inhibitor cocktail (Sigma P8849). All
steps were performed at 4C. The lysate was spun at 43,152 3 g, 45 min to
pellet-insoluble material. The supernatant was incubated with glutathione
sepharose (GS-4B; GE Healthcare), 2 hr, then washed with 100 ml lysis buffer,
1 hr, followed by 100 ml of TEV cleavage buffer (50 mM Tris, pH 7.4, 50 mM
NaF, 5 mM sodium pyrosphophate, 10 mM b-glycerophosphate, 1 mM
TCEP, 0.5 mM sodium orthovanadate, 0.25% (w/v) CHAPS). GST- PKCbII
was cleaved on-resin with TEV protease overnight. The supernatant from the
TEV cleavage reaction was applied to a Q-sepharose anion exchange column
(GE Healthcare) and PKCbII eluted with a linear NaCl gradient in 50 mM Tris,
pH 8.0, 1 mM TCEP. Fractions containing PKCbII were pooled, concentrated,
and loaded onto a Superdex 200 (10/300 GL; GE Healthcare) gel-filtration
column equilibrated in 20 mM Tris, pH 8.0, 100 mM NaCl, 2 mM MgCl2,
1 mM TCEP. PKCbII was eluted as a single peak with a retention time consis-
tent with a globular, monomeric protein of 78 kDa.
Crystallization and Structure Determination
Crystals of wild-type and SEC mutant PKCbII grew over 2 days from fresh
protein preparations. SDS-PAGE analysis of the drops from which crystals
were harvested showed no indication of PKCbII degradation (Figure S1A).
PKCbII was combined with 1 mM AMPPNP (Sigma) and concentrated to
2 mg/ml. Both wild-type and SEC proteins crystallized; however the best dif-
fractors were obtained for the SEC mutant. Hexagonal crystals of the SEC
mutant were grown in 1%–4% (w/v) PEG 8000, 100 mM Tris, pH 8.5, either
attached to the plate or to a skin of denatured protein on the surface of the
drop. Multiple crystals were mounted in a loop, cryoprotected in 20% ethylene
glycol, and drop frozen in liquid nitrogen. Data were collected on the microfo-
cus beamline GM/CA-CAT ID23-B at the Advanced Photon Source (APS).
Crystals in the loop were detected and centered in the beam by using the
RASTER software to scan the loop for diffraction. A complete dataset from
a single crystal with unit cell dimensions a = b = 114.27 A˚, c = 170.84 A˚ was
collected to 4.0 A˚ resolution in spacegroup P3221. The structure of PKCbII
was solved by molecular replacement using the program Phaser (McCoy
et al., 2007). The catalytic domain of PKCbII (PDB ID: 2I0E) and the C2 domain
of PKCbII (PDB ID: 1A25) were used as search models. The C1B domain was
located in themap using the interatomic distance between the zinc ions to help
position it, and this was followed by rigid body refinement. No density was
observed for the N-terminal pseudosubstrate segment and C1A domain
(residues 1–100) and the V3 linker (residues 293–338). Refinement was carried
out using the deformable elastic network (DEN) model as implemented in CNS
1.3 (Schroder et al., 2010) with the catalytic and C2 domains as separate
restraint groups. The DEN parameters g and kwere set at 0.5 and 0.1, respec-
tively. Residues 353 and 619–639 of the catalytic domain were omitted from
the restraint group. Density syntheses following DEN refinement were instru-
mental in determining the position of the novel helix. The refined structure
has no residues in disallowed regions of the Ramachandran plot and only
ten residues in generously allowed regions (Laskowski et al., 1993). The
MolProbity (Davis et al., 2007) all atom clash score was 41.6, placing the struc-
ture in the 64th percentile (with 100th best) of structures refined at 3.0 A˚ or
lower resolution. The MolProbity protein geometry score was 3.5, placing
the structure in the 70th percentile of structures at 3.25–4.25 A˚ resolution.
Clashes and stereochemical outliers were more common in the C1B domain,
the C1B-C2 linker, and the NFD helix and adjacent residues, which were not
constrained by the DEN model.
In Vivo Translocation Assay
Wild-type and mutant PKCbII proteins were analyzed for their ability to trans-
locate to membranes in a phorbol ester-dependent manner in vivo. HEK293
GnTI cells were cotransfected with mammalian expression vectors containing
PDK-1 and PKCbII and grown at 37C for 48 hr. Cells were stimulated with 80
pM–1 mM phorbol 12-myristate 13-acetate (PMA) (Sigma) for 15 min at 37C,
harvested, and snap frozen on dry ice. Cells were resuspended in 500 ml PKC
lysis buffer, sonicated on low power on ice, 15 s, 1 s pulses followed by 1 s off.64 Cell 144, 55–66, January 7, 2011 ª2011 Elsevier Inc.The lysate was spun at 9003 g, 5min, 4C to discard the organelles and enrich
plasma membrane. The supernatant was then transferred to a fresh tube and
spun at 100,000 3 g, 30 min, 4C. The supernatant (cytosolic fraction) was
transferred to a fresh tube on ice. Ten microliters of a 3:1 mixture of cytosolic
or membrane fraction with 43 LDS gel loading buffer (Invitrogen) containing
50 mM b-mercaptoethanol was loaded on a 4%–12% polyacrylamide gel
(Invitrogen). The gel was blotted onto PVDF and PKCbII detected using an
anti-PKCbII primary antibody (BD Biosciences BD610128) and Alexa Fluor
488-conjugated goat anti-rabbit IgG secondary antibody (Invitrogen). Cyto-
solic PKCbII fractions were quantitated using a Typhoon scanner at 519 nm.
Small-Angle X-Ray Scattering
Wild-type PKCbII samples were prepared with and without the nonhydrolyz-
able nucleotide analog AMPPNP. Data were collected on 25 mM samples in
20mM Tris, pH 8.0, 100mMNaCl, 2 mMMgCl2, 1 mMTCEP ± 1mMAMPPNP
at SSRL beamline BL4-2. Data reduction and analysis were performed using
the beamline software SAStool. The program AutoGNOM of the ATSAS suite
(Petoukhov et al., 2007) was used to generate P(r) curves and to determine
maximum dimension (Dmax) and RG from the scattering intensity curve (I(q)
versus q) in an automatic, unbiased manner, although rounds of manual fitting
in GNOM (Svergun, 1992) were used to verify these values. Ab initio molecular
envelopes were computed by the programs DAMMIF (Franke and Svergun,
2009) and GASBOR (Svergun et al., 2001). Multiple iterations of DAMMIF
and GASBOR were averaged using DAMAVER (Volkov and Svergun, 2003),
the core residues fixed, and the model subjected to a further cycle of DAMMIN
(Svergun, 1999) refinement.
SAXS Structural Refinement
Monte Carlo simulations of PKCbII were performed using an energy function
and simulation model developed to study multiprotein complexes (Kim and
Hummer, 2008; Kim et al., 2008; Ren et al., 2009; Ro´ _zycki et al., 2011). In
this model, folded protein domains are represented as rigid bodies. Here,
the catalytic domain together with the bound C1B domain and the pseudosub-
strate peptide modeled on the basis of PKA (PDB entries 3FHI and 2QCS)
(Kim et al., 2005, 2007) are treated as one rigid body. C1A and C2 domains
are modeled as two separate rigid bodies. The interactions between the
domains are treated at the residue level with amino-acid-dependent pair
potentials and Debye-Hu¨ckel-type electrostatic interactions. Flexible linker
peptides connecting the rigid domains are represented as amino acid beads
on an excluded-volume random-coil polymer. We adapted the CRYSOL
algorithm (Svergun et al., 1995) to calculate SAXS intensity I(q) for all simulated
structures. CRYSOL default parameters were used in the calculation. To esti-
mate the uncertainty of computed intensity I(q), we varied the hydration layer
electron density between 0.015 e/A˚3 and 0.03 e/A˚3 (Yang et al., 2009). To
gain insights into the protein-relevant configurations, we selected several
structures whose SAXS profiles I(q) best fit the experimental data (Figures
5B–5D). We used chi-square as a measure of discrepancy between the
computed SAXS curves and experimental data. The error term that enters
the c2 formula contains the statistical error of experiment and the uncertainty
of computed intensity I(q). Only structures with c2 < 1.5 were considered.
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